What are the recommendations for testosterone supplementation in a perimenopausal woman?

Testosterone Supplementation in Perimenopausal Women

Testosterone supplementation should only be prescribed to perimenopausal women who have been formally diagnosed with hypoactive sexual desire disorder (HSDD) after a comprehensive biopsychosocial assessment—it is not recommended for general use in perimenopause for other symptoms like fatigue, mood, cognition, or well-being. 1

Evidence-Based Indication

The 2019 Global Consensus Position Statement provides Level I, Grade A evidence that the only evidence-based indication for testosterone therapy in women is for postmenopausal women with HSDD 1. The 2014 Endocrine Society guidelines similarly recommend against generalized testosterone use for sexual dysfunction except for the specific diagnosis of HSDD 2.

Critical Distinction for Perimenopausal Women

The evidence base is predominantly in postmenopausal women, not perimenopausal women. Recent research acknowledges that "only limited research supports its benefit for HSDD treatment in women of late reproductive age" 3. This is a crucial caveat—the robust data supporting testosterone for HSDD comes from postmenopausal populations, and extrapolation to perimenopause requires clinical judgment.

Diagnostic Requirements Before Prescribing

Do not prescribe testosterone without first establishing:

• Formal diagnosis of HSDD through biopsychosocial assessment that evaluates:

  • Neuroendocrine factors
  • Physical health status
  • Interpersonal relationship quality
  • Psychological distress
  • Cultural/religious influences on sexuality 1

• Exclusion of other causes of sexual dysfunction (relationship issues, depression, medications, other medical conditions)

• Baseline testosterone level measured in the morning 1, 2

Important pitfall: The 2014 Endocrine Society explicitly recommends against making a diagnosis of "androgen deficiency syndrome" in healthy women because no well-defined syndrome exists and testosterone levels do not correlate reliably with symptoms 2. Do not prescribe based solely on low testosterone levels.

Formulation and Dosing

Use transdermal (non-oral) preparations only:

• Avoid oral testosterone—it causes adverse lipid profiles with negative effects on HDL and LDL cholesterol (Level I, Grade A) 1

• Transdermal testosterone (patches, gels, creams) shows no adverse lipid effects short-term 1

• Target physiologic premenopausal female testosterone concentrations—avoid supraphysiologic dosing 1

• Avoid testosterone pellets and injections as these often result in supraphysiologic levels (Expert Opinion) 1

Practical Reality

No FDA-approved testosterone formulation exists for women in the United States 4, 3. The FDA labels provided are for male hypogonadism and explicitly contraindicate use in women who are pregnant 4.

If prescribing off-label:

• Use approved male formulations at reduced doses to achieve female physiologic ranges (Expert Opinion) 1
• Avoid compounded "bioidentical" preparations due to lack of efficacy/safety data and quality control concerns 1
• If compounded products are necessary, ensure pharmacy compliance with Good Manufacturing Practice 1

Monitoring Protocol

Baseline:

• Morning total testosterone level
• Lipid panel
• Liver function tests
• Hemoglobin/hematocrit 2

Follow-up:

• Testosterone level at 3-6 weeks after initiation 1, 2
• Testosterone level every 6 months thereafter to screen for overuse and androgen excess 1, 2
• Assess clinical response and signs of androgen excess at each visit

Discontinue if no benefit by 6 months (Level IB, Grade C) 1

Safety Profile

Short-term safety (up to 24 months):

• Mild increases in acne and facial/body hair in some women (Level I, Grade A) 1
• No alopecia, clitoromegaly, or voice changes at physiologic doses 1
• No increases in blood pressure, glucose, or HbA1c 1
• No increase in mammographic breast density 1
• No increased breast cancer risk short-term 1
• No serious adverse events at physiologic doses 1

Critical safety gaps:

• Safety data beyond 24 months do not exist (Level I, Grade A) 1
• Insufficient data on myocardial infarction or death 1
• Non-significant trend toward DVT risk (confounded by concurrent estrogen use) 1
• Long-term breast cancer risk unknown 1

Contraindications and Cautions

Absolute contraindications:

• Pregnancy (testosterone causes fetal harm) 4
• Hormone-sensitive breast cancer (Expert Opinion) 1

Relative cautions:

• High cardiometabolic disease risk (trials excluded these patients) 1
• Cardiac, renal, or hepatic disease 4

What NOT to Prescribe Testosterone For

The evidence does NOT support testosterone for:

• Infertility
• Cognitive dysfunction
• Cardiovascular health
• Metabolic dysfunction
• Bone health
• General well-being or energy
• Mood symptoms as primary indication 2

While recent observational studies suggest testosterone may improve mood and cognition in menopausal women 5, 6, 7, these are not evidence-based indications per current guidelines. The 2014 Endocrine Society provides strong recommendations (Level 1) against generalized use for these purposes 2.

Clinical Algorithm

For a perimenopausal woman requesting testosterone:

1. Assess her specific complaint: Is it primarily low sexual desire causing distress?

   • If NO → Do not prescribe testosterone; address actual symptoms appropriately
   • If YES → Proceed to step 2

2. Conduct biopsychosocial assessment for HSDD:

   • Rule out relationship issues, depression, medications, medical conditions
   • Assess psychological, interpersonal, and cultural factors
   • Consider psychotherapy or multimodal treatment 1

3. If HSDD confirmed:

   • Obtain baseline morning testosterone, lipids, LFTs, CBC
   • Counsel about limited evidence in perimenopause (stronger data in postmenopause)
   • Discuss lack of long-term safety data beyond 2 years
   • Explain off-label use and lack of FDA-approved female formulations

4. If proceeding with trial:

   • Prescribe transdermal preparation at low dose
   • Recheck testosterone at 3-6 weeks, adjust to achieve premenopausal female range
   • Monitor every 6 months for efficacy and androgen excess
   • Discontinue if no benefit by 6 months

Common Pitfalls to Avoid

• Do not prescribe based on "low testosterone" alone—levels don't correlate with symptoms 2
• Do not use oral testosterone—adverse lipid effects 1
• Do not use pellets or injections—risk of supraphysiologic levels 1
• Do not prescribe for vague symptoms like fatigue or mood without HSDD diagnosis 2
• Do not forget to monitor—overuse and androgen excess can occur 1, 2
• Do not continue beyond 6 months without benefit 1